Cipla Limited (BOM:500087)
1,232.90
+4.00 (0.33%)
At close: Apr 21, 2026
Cipla Revenue
Cipla had revenue of 69.63B INR in the quarter ending December 31, 2025, with 0.02% growth. This brings the company's revenue in the last twelve months to 279.67B, up 4.67% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.67B
Revenue Growth
+4.67%
P/S Ratio
3.56
Revenue / Employee
9.23M
Employees
30,313
Market Cap
995.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 345.83B |
| Lupin | 261.51B |
| Torrent Pharmaceuticals | 127.42B |
| Jubilant Pharmova | 79.18B |
| Abbott India | 68.24B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 38.01B |
Cipla News
- 5 hours ago - Pharma sector stocks today, April 22: Natco Pharma up 1.4%, Lupin falls 1.01%, Cipla down 0.73% - Business Upturn
- 4 days ago - Cipla receives two inspectional observations from USFDA at Goa facility - Business Upturn
- 9 days ago - Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77% - Business Upturn
- 19 days ago - Cipla Gets FDA Approval For Generic Nintedanib Capsules - Nasdaq
- 22 days ago - Cipla appoints new senior management personnel amid leadership changes - Business Upturn
- 26 days ago - Cipla, Bajaj Finserv & more: Top stocks to watch today - The Times of India
- 26 days ago - Cipla's Global Chief Scientific Officer Pradeep Bhadauria resigns - Business Upturn
- 4 weeks ago - Nifty 50 top losers today, March 24: Coal India, Power Grid, Adani Enterprises, Sun Pharma and Cipla - Business Upturn